ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial by Pedro Giavina-Bianchi, MD, PhD, Eric Cua, MD, Karine Risso, MD, Véronique Mondain, MD, Anaïs Vissian, MSc, Cécile Joie, MSc, Philippe Pouletty, MD, Paul Gineste, PharmD, Hartmut J. Ehrlich, MD, PhD, Jorge Kalil, MD, PhD

Get full text